Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChiP: Carboplatin in Pretreated Metastatic Castration-Resistant Prostate Cancer
2019-002104-40Phase 2Active
- Sponsor
- Spanish National Cancer Research Centre
- Start
- Aug 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts), sponsored by Spanish National Cancer Research Centre. Primary endpoint: Objective response rate (ORR). Started Aug 2019; status: active.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-002104-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002104-40.